InsidersTradesSigma
Track the Sol-Gel Technologies Ltd. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Sol-Gel Technologies Ltd. has published 28 insider filings. Market capitalisation: €226.2m. The latest transaction was reported on 3 September 2026 (Acquisition). Among the most active insiders: Opaleye Management Inc.. The full history is accessible without an account.
28
Insider Decl.
n/a
Thresholds
€6m
28 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Sol-Gel Technologies Ltd. Strong Buy (bullish), based on 3 analysts. Average price target: US$196.67.
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,751 of 29,062 companies
19.6
score / 100
Value32
Quality7
FCF yld0.1%
Earn yld-2.7%
EV/EBITDA·
ROE-41%
Gross mgn·
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations28 total
783 shares@ US$69.52Ordinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-041363:0
Canonical exit: 30 Nov 2026 (T+90)
900 shares@ US$68.9489Ordinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-041363:1
Canonical exit: 1 Dec 2026 (T+90)
10,000 shares@ US$71.39690.32% mcap10.5% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:0
Canonical exit: 26 Nov 2026 (T+90)
20,113 shares@ US$68.42030.61% mcap20.3% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:1
Canonical exit: 26 Nov 2026 (T+90)
5,000 shares@ US$68.810.15% mcap5.1% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:2
Canonical exit: 26 Nov 2026 (T+90)
5,000 shares@ US$68.2350.15% mcap5.1% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:3
Canonical exit: 29 Nov 2026 (T+90)
217 shares@ US$69.100.0067% mcap0.2% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:4
Canonical exit: 29 Nov 2026 (T+90)
951 shares@ US$71.500.029% mcap1.7% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-038304:0
Canonical exit: 10 Nov 2026 (T+90)
920 shares@ US$73.43040.028% mcap1.8% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-033354:1
Canonical exit: 12 Oct 2026 (T+90)
775 shares@ US$73.88730.024% mcap1.5% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-033354:0
Canonical exit: 11 Oct 2026 (T+90)
300 shares@ US$73.690.0089% mcap0.6% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-032859:0
Canonical exit: 6 Oct 2026 (T+90)
229 shares@ US$73.950.0068% mcap0.5% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-032859:1
Canonical exit: 8 Oct 2026 (T+90)
1,500 shares@ US$67.98330.037% mcap50.0% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-023056:0
Canonical exit: 10 Aug 2026 (T+90)
34,665 shares@ US$72.0096.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-012354:0
Canonical exit: 22 Jun 2026 (T+90)
100 shares@ US$58.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-007306:0
Canonical exit: 3 May 2026 (T+90)
291 shares@ US$63.000.5% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-007330:0
Canonical exit: 14 May 2026 (T+90)
100 shares@ US$58.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-005094:0
Canonical exit: 3 May 2026 (T+90)
100 shares@ US$57.050.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-004234:0
Canonical exit: 27 Apr 2026 (T+90)
2,173 shares@ US$56.56813.2% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-003468:0
Canonical exit: 22 Apr 2026 (T+90)
2,394 shares@ US$41.91642.6% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-000588:0
Canonical exit: 2 Apr 2026 (T+90)
8,638 shares@ US$41.85399.4% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-029866:0
Canonical exit: 29 Mar 2026 (T+90)
1,019 shares@ US$41.15371.3% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-029359:0
Canonical exit: 22 Mar 2026 (T+90)
2,735 shares@ US$40.37013.5% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-028550:0
Canonical exit: 17 Mar 2026 (T+90)
87 shares@ US$40.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-027959:0
Canonical exit: 12 Mar 2026 (T+90)
444 shares@ US$39.49730.6% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-026848:0
Canonical exit: 5 Mar 2026 (T+90)
25 of 28 declarations
关于 Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. 是一家在美国纳斯达克（美国）上市的专业生物制药公司，专注于皮肤病学领域。该公司成立于 1997 年 10 月 28 日，总部位于以色列内斯齐奥纳的魏茨曼科学园。其核心战略是开发和商业化用于治疗严重、罕见和高度未满足需求的皮肤病的局部疗法，并由专有的微囊化制剂平台提供支持，旨在改善皮肤病活性成分的局部递送和耐受性。（[ir.sol-gel.com](https://ir.sol-gel.com/resources/investor-faqs?utm_source=openai)） Sol-Gel 的商业历史以两种 FDA 批准的产品为基础：用于治疗成人和 9 岁及以上儿童寻常痤疮的 TWYNEO®，以及用于治疗成人酒渣鼻炎症性病变的 EPSOLAY®。这些批准表明了公司通过临床开发和监管审查推进皮肤病资产的能力。最近，Sol-Gel 已将越来越多的注意力转向其专有管线，其中以 SGT-610 为主导，这是一种局部帕替德吉凝胶，目前处于 III 期开发阶段，用于预防 Gorlin 综合征患者的新发基底细胞癌病变。该管线还包括 SGT-210，一种局部厄洛替尼候选药物，正在研究用于 Darier 病和其他罕见角化病。（[ir.sol-gel.com](https://ir.sol-gel.com/node/8896?utm_source=openai)） 从竞争角度来看，Sol-Gel 相对于大型全球皮肤病学和专业制药集团而言仍然是一个利基市场参与者，但它通过专注于局部制剂专业知识、已证实的监管执行能力以及美国以外的合作驱动商业化模式，开辟了差异化的形象。该公司已签署多项 TWYNEO 和 EPSOLAY 的非美国许可协议，包括在欧洲、南非、澳大利亚和新西兰的安排，这扩大了地理范围，同时减少了对大型内部销售基础设施的需求。（[ir.sol-gel.com](https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-announces-signing-six-exclusive-license-agreements?utm_source=openai)） 最近的一项关键进展是 2025 年 4 月将 EPSOLAY 和 TWYNEO 的美国权利出售给 Mayne Pharma，此前 Sol-Gel 与 Galderma 的独家美国许可协议已相互终止。该交易实质性地重塑了公司在美国的商业风险敞口，并使临床管线，特别是 SGT-610，在投资案例中变得更加核心。在 2026 年 3 月，Sol-Gel 还完成了一项新的承销发行，这强调了随着公司继续资助临床开发并为未来潜在的商业化做准备，流动性管理和资本获取仍然是重要的优先事项。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1684693/000117891325002946/exhibit_99-1.htm?utm_source=openai)）
